Healthy
Conditions
Brief summary
Study to investigate safety, tolerability and pharmacokinetics of KUC 7483
Interventions
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
30 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests * No finding deviating from normal and of clinical relevance * No evidence of a clinically relevant concomitant disease 2. Age ≥30 and Age ≤60 years 3. BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index) 4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
Exclusion criteria
* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of relevant orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial * Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial * Participation in another trial with an investigational drug within two months prior to administration or during the trial * Smoker (\> 10 cigarettes or \> 3 cigars of \> 3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (more than 60 g/day) * Drug abuse * Blood donation (more than 100 mL within four weeks prior to administration or during the trial) * Excessive physical activities (within one week prior to administration or during the trial) * Any laboratory value outside the reference range of clinical relevance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with clinically significant findings in physical examination | up to 8 days after last drug administration | — |
| Number of subjects with clinically significant changes in vital signs | up to 8 days after last drug administration | Blood pressure, Pulse Rate, Respiratory Rate, body temperature, orthostatic testing |
| Number of subjects with clinically significant findings in 12-lead ECG (electrocardiogram) | up to 8 days after last drug administration | — |
| Number of subjects with clinically significant changes in laboratory parameters | up to 8 days after last drug administration | — |
| Number of subjects with adverse events | up to 8 days after last drug administration | — |
| Assessment of tolerability by investigator on a 3-point rating scale | within 8 days after last drug administration | — |
| Number of subjects with clinically significant changes in special laboratory parameters | up to 24 hours after drug administration | Tropanin I, Insulin, C-Peptide, Glucagon, free fatty acids and faecal occult blood testing |
Secondary
| Measure | Time frame |
|---|---|
| MRTpo (mean residence time of the analyte in the body after oral administration) | up to 48 hours after drug administration |
| CL/F (apparent clearance of the analyte in the plasma after extravascular administration) | up to 48 hours after drug administration |
| Aet1-t2 (amount of the analyte that is eliminated in urine from the time point t1 until time point t2) | up to 48 hours after drug administration |
| fet1-t2 (fraction of administered drug excreted unchanged in urine from the time point t1 until time point t2) | up to 48 hours after drug administration |
| CLR,t1-t2 (renal clearance of the analyte determined from the time point t1 until time point t2) | up to 48 hours after drug administration |
| Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) | up to 48 hours after drug administration |
| Cmax (maximum measured concentration of the analyte in plasma) | up to 48 hours after drug administration |
| tmax (time from dosing to the maximum concentration of the analyte in plasma) | up to 48 hours after drug administration |
| AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) | up to 48 hours after drug administration |
| AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) | up to 48 hours after drug administration |
| λz (terminal rate constant of the analyte constant in plasma) | up to 48 hours after drug administration |
| t1/2 (terminal half-life of the analyte in plasma) | up to 48 hours after drug administration |
Outcome results
None listed